Atreca to Present at Upcoming Investor Conferences
Atreca, a clinical-stage biotechnology company trading under NASDAQ: BCEL, announces its participation in several upcoming conferences. The company will present at the Cowen 6th Annual IO Next Summit on November 11, 2022, followed by the Stifel Healthcare Conference on November 15-16, 2022, and the Evercore ISI HealthCONx Conference from November 29 to December 1, 2022. Live webcasts will be available on its website, with replays accessible for 30 days post-event. Atreca focuses on antibody-based immunotherapeutics, including its lead candidates ATRC-101 and ATRC-301.
- None.
- None.
SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming conferences:
Cowen 6th Annual IO Next Summit
November 11, 2022
Fireside Chat: 2:40-3:00 am EST, November 11, 2022
Stifel Healthcare Conference
November 15-16, 2022
Fireside Chat: 8:00-8:30 am EST, November 15, 2022
Evercore ISI HealthCONx Conference
November 29 - December 1, 2022
Fireside Chat: 9:40-10:00 am EST, December 1, 2022
Live webcasts of the presentations can be accessed through the Events & Presentations section of the Company's website at http://ir.atreca.com. An archived replay of each presentation will be available on the Company's website for 30 days following the live broadcast.
About Atreca, Inc.
Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101, a monoclonal antibody targeting a novel ribonucleoprotein complex, as well as ATRC-301, an antibody drug conjugate targeting a novel epitope on EphA2. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients, and ATRC-301 is in IND-enabling studies. For more information on Atreca, please visit www.atreca.com.
Forward-Looking Statements
This release contains statements regarding matters that are not historical facts that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding our strategy and future plans, including statements regarding the development of ATRC-101, ATRC-301, and our preclinical and clinical plans and the timing thereof. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.
Contacts
Atreca, Inc.
Herb Cross
Chief Financial Officer
info@atreca.com
Investors:
Alex Gray, 650-779-9251
agray@atreca.com
Media:
Julia Fuller, 858-692-2001
Julia@fordhutmanmedia.com
FAQ
What conferences will Atreca present at in November 2022?
When is Atreca's fireside chat at the Cowen Summit?
Where can I find the live webcasts of Atreca's presentations?
What are the lead product candidates of Atreca?
What is the focus of Atreca's research?
